Meeting
2014 ASCO Annual Meeting
Randomized phase 2 study of carboplatin plus irinotecan (CI) versus carboplatin plus amrubicin (CA) for extensive disease small-cell lung cancer (ED-SCLC): NJLCG0901.
Authors
Yosuke Kawashima
Sendai Kousei Hospital, Sendai, Japan
Yosuke Kawashima , Naoto Morikawa , Shunichi Sugawara , Makoto Maemondo , Toshiyuki Harada , Masao Harada , Akira Inoue , Yuka Fujita , Terufumi Kato , Hiroshi Yokouchi , Hiroshi Watanabe , Kazuhiro Usui , Toshiro Suzuki , Satoshi Oizumi , Hiroki Nagai , Mariko Kanbe , Toshihiro Nukiwa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
UMIN000008970
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 7521)
DOI
10.1200/jco.2014.32.15_suppl.7521
Abstract #
7521
Poster Bd #
14
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Trends in treatment patterns associated with small cell lung cancer in a U.S. Medicare population.
First Author: Robert A. Ramirez
Poster
2014 ASCO Annual Meeting
Randomized phase 2 trial comparing amrubicin (A) with re-challenge of platinum doublet (P) in patients (pts) with sensitive-relapsed small-cell lung cancer (SCLC).
First Author: Atsushi Nakamura
Poster
2016 ASCO Annual Meeting
Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).
First Author: Anne C. Chiang
Poster
2014 ASCO Annual Meeting
Randomized phase III trial in extensive-disease small cell lung cancer comparing first-line etoposide to topotecan in combination with platinum.
First Author: Morten Mau-Soerensen